keyword
MENU ▼
Read by QxMD icon Read
search

Gastroesophageal junction cancer

keyword
https://www.readbyqxmd.com/read/29674442/first-report-of-dramatic-tumor-responses-with-ramucirumab-and-paclitaxel-after-progression-on-pembrolizumab-in-two-cases-of-metastatic-gastroesophageal-adenocarcinoma
#1
Sakti Chakrabarti, Haidong Dong, Harshita R Paripati, Helen J Ross, Harry H Yoon
Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma...
April 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29670922/clinicopathological-features-and-increased-expression-of-toll-like-receptor-4-of-gastric-cardia-cancer-in-a-high-risk-chinese-population
#2
Guangcan Chen, Muming Xu, Jingyao Chen, Liangli Hong, Wenting Lin, Shukun Zhao, Guohong Zhang, Guo Dan, Shuhui Liu
The incidence of gastric cardia cancer (GCC) is high in China. However, the clinicopathological characteristics and the carcinogenesis of GCC are unclear. Toll-like receptor 4 (TLR4) is an important innate immunity receptor and has a role in non-GCC (NGCC). We compared the clinicopathological characteristics of GCC patients from a high-risk area in China to esophageal cancer (EC) patients. Immunohistochemistry for TLR4 was performed in 201 histological samples of normal gastric cardia mucosa ( n = 11), gastric cardia inflammation ( n = 87), and GCC ( n = 103)...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29668913/defining-pneumonia-after-esophagectomy-for-cancer-validation-of-the-uniform-pneumonia-score-in-a-high-volume-center-in-north-america
#3
M F J Seesing, A Wirsching, P S N van Rossum, T J Weijs, J P Ruurda, R van Hillegersberg, D E Low
Surgery is a central component of multimodality therapy for esophageal and gastroesophageal junction cancer. Pneumonia is a common sequela of esophagectomy, leading to an increase in intensive care unit stay, hospital stay, readmission rates, and postoperative mortality. Developing strategies to reduce pneumonia after esophagectomy is hampered by the absence of a standardized methodology for defining pneumonia. This study aims to validate the Uniform Pneumonia Score (UPS) in a high volume center in the USA...
April 14, 2018: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/29663302/multivisceral-resection-for-locally-advanced-gastric-and-gastroesophageal-junction-cancers-11-year-experience-at-a-high-volume-north-american-center
#4
J C Molina, A Al-Hinai, A Gosseling-Tardif, P Bouchard, J Spicer, D Mulder, C L Mueller, L E Ferri
INTRODUCTION: The oncologic benefit of multivisceral en bloc resections for T4 gastroesophageal tumors has been questioned, given the increased morbidity associated. We thus sought to investigate the surgical and oncologic outcomes of curative-intent en bloc multivisceral resections for T4 gastroesophageal carcinomas. METHODS: Between 2005 and 2016, 35 of the 525 patients who had gastric or EGJ carcinomas underwent curative-intent multivisceral resections for direct invasion or adhesion to adjacent organs...
April 16, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29611027/prevalence-and-prognostic-significance-of-extramural-venous-invasion-in-patients-with-locally-advanced-esophageal-cancer
#5
Zohra Faiz, Lotte J W Huijgen, H J Alqethami, J G M Burgerhof, Gursah Kats-Ugurlu, John T M Plukker
BACKGROUND: Extramural venous invasion (EMVI) is a known adverse prognostic factor in patients with colorectal carcinoma. The prevalence and significance of EMVI in esophageal cancer (EC) patients is still unclear. METHODS: From a prospectively maintained database, we retrospectively reviewed the resection specimens of patients with pathologic locally advanced (pT3/T4/N0-3) EC who were treated with curative intent between 2000 and 2015. Patients with previous malignancies and gastroesophageal junction (type II/III) tumors were excluded...
April 2, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29601052/the-role-of-neoadjuvant-chemoradiotherapy-in-multimodality-treatment-of-esophageal-or-gastroesophageal-junction-cancer
#6
COMMENT
Fredrik Klevebro, Magnus Nilsson
No abstract text is available yet for this article.
January 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29594228/vmat-radiation-induced-nausea-and-vomiting-in-adjuvant-breast-cancer-radiotherapy-the-incidental-effect-of-low-dose-bath-exposure
#7
G Lazzari, A Terlizzi, M G Leo, G Silvano
Background and purpose: To investigate the hypothesis on low-dose bath exposure related to radiation-induced nausea and vomiting (RINV) in adjuvant breast volumetric modulated arch therapy (VMAT). Methods and materials: A total of 106 consecutive breast cancer patients (pts) treated with adjuvant radiotherapy (RT) with VMAT from January 2013 to May 2016 were evaluated retrospectively. For each pt, a planning CT was reimported and the coeliac plexus and gastroesophageal junction with gastric mouth (GEJCPs) were contoured as a new organ at risk (OAR) in the upper abdominal area...
December 2017: Clinical and Translational Radiation Oncology
https://www.readbyqxmd.com/read/29552209/gastric-cancer-with-brain-metastasis-and-the-role-of-human-epidermal-growth-factor-2-status
#8
Luigi Cavanna, Pietro Seghini, Camilla Di Nunzio, Elena Orlandi, Emanuele Michieletti, Elisa Maria Stroppa, Patrizia Mordenti, Chiara Citterio, Stefano Vecchia, Adriano Zangrandi
Central nervous system (CNS) metastases from cancers of the gastrointestinal tract (GIT) are rare, and occur in 0.16-0.69% of patients with gastric or gastro-esophageal (GE) junction cancer. Overexpression of the human epidermal growth factor 2 (HER-2) is associated with poor prognosis in the absence of HER-2-targeted therapy, and with an increased incidence of CNS metastases in patients with breast cancer. The role of HER-2 overexpression in CNS metastases is not well known in gastric adenocarcinoma. The purpose of the present retrospective study was to assess the incidence of CNS metastases and to evaluate the associations between the CNS and HER-2 status in a series of consecutive patients with gastric or GE junction cancer...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29544445/long-term-trastuzumab-herceptin%C3%A2-treatment-in-a-continuation-study-of-patients-with-her2-positive-breast-cancer-or-her2-positive-gastric-cancer
#9
Volkmar Müller, Michael Clemens, Jacek Jassem, Nedal Al-Sakaff, Petra Auclair, Eveline Nüesch, Debbie Holloway, Mona Shing, Yung-Jue Bang
BACKGROUND: Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on long-term H treatment of patients. The Rollover Protocol (ROP) Study was conducted to report safety data for patients with HER2-positive locally advanced/metastatic breast and gastric/GEJ cancer who have received long-term H therapy (≥ 5 years and ≥ 3 years for breast and gastric/GEJ cancer, respectively)...
March 15, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29543932/safety-and-efficacy-of-pembrolizumab-monotherapy-in-patients-with-previously-treated-advanced-gastric-and-gastroesophageal-junction-cancer-phase-2-clinical-keynote-059-trial
#10
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A Wainberg, Daniel V Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H Ko, Geoffrey Ku, Philip Philip, Peter C Enzinger, Yung-Jue Bang, Diane Levitan, Jiangdian Wang, Minori Rosales, Rita P Dalal, Harry H Yoon
Importance: Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. Objective: To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously treated gastric or gastroesophageal junction cancer. Design, Setting, and Participants: In the phase 2, global, open-label, single-arm, multicohort KEYNOTE-059 study, 259 patients in 16 countries were enrolled in a cohort between March 2, 2015, and May 26, 2016...
March 15, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29508095/ramucirumab-for-the-treatment-of-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma-following-disease-progression-on-first-line-platinum-or-fluoropyrimidine-containing-combination-therapy-in-japanese-patients-a-phase-2-open-label-study
#11
Kensei Yamaguchi, Kazumasa Fujitani, Fumio Nagashima, Yasushi Omuro, Nozomu Machida, Tomohiro Nishina, Toshiko Koue, Mika Tsujimoto, Kaijiro Maeda, Taroh Satoh
BACKGROUND: Ramucirumab, a monoclonal antibody vascular endothelial growth factor receptor-2 antagonist, given as monotherapy improved survival in a global phase 3 study (REGARD) of patients with gastric cancer. However, REGARD did not include Japanese patients. This study evaluated the efficacy and safety of ramucirumab monotherapy in Japanese patients with advanced gastric cancer. METHODS: This multicenter, open-label, nonrandomized phase 2 study (Clinicaltrials...
March 5, 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29500656/clinicopathological-features-and-endoscopic-findings-of-her2-positive-gastric-cancer
#12
Yasuhiro Oono, Takeshi Kuwata, Kenji Takashima, Yusuke Yoda, Hiroaki Ikematsu, Kohei Shitara, Takahiro Kinoshita, Tomonori Yano
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) expression in gastric cancer is highly heterogeneous. Therefore, it is important to take endoscopic samples from appropriate tumor sites. METHODS: Between January 2008 and April 2015, patients with gastric or gastroesophageal junction cancer with histologically confirmed adenocarcinoma were included. Surgical samples or endoscopic biopsy samples were examined for HER2 using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)...
March 2, 2018: Surgical Endoscopy
https://www.readbyqxmd.com/read/29488121/a-multicenter-randomized-trial-comparing-efficacy-and-safety-of-paclitaxel-capecitabine-and-cisplatin-capecitabine-in-advanced-gastric-cancer
#13
Zhihao Lu, Xiaotian Zhang, Wei Liu, Tianshu Liu, Bing Hu, Wei Li, Qingxia Fan, Jianming Xu, Nong Xu, Yuxian Bai, Yueyin Pan, Qing Xu, Wei Bai, Li Xia, Yong Gao, Wenling Wang, Yongqian Shu, Lin Shen
BACKGROUND: We compared efficacy and safety of paclitaxel/capecitabine therapy followed by capecitabine for maintenance (PACX) versus cisplatin/capecitabine therapy (XP) in advanced gastric cancer. METHODS: Multicenter, randomized, phase III trial was conducted in China (December 2009-February 2014). Adults (n = 320) with histologically confirmed, untreated metastatic/unresectable gastric or gastroesophageal junction adenocarcinoma; with ≥ 1 measureable lesions according to Response Evaluation Criteria in Solid Tumors 1...
February 27, 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29430123/testicular-metastasis-from-recurrent-gastroesophageal-junction-adenocarcinoma-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-findings
#14
Ishan Garg, Maria Jose Baladron Zanetti, Ayse Tuba Kendi
Testicular metastasis from gastroesophageal junction (GEJ) adenocarcinoma is a very rare condition. A 57-year-old male with a history of neoadjuvant chemotherapy and surgery for HER-2-positive GEJ adenocarcinoma underwent a follow-up 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). It revealed multiple metastases including bilateral testicular and L4 laminar metastasis. The patient received multiple chemotherapies, but follow-up PET/CT showed interval progression of disease...
January 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/29416812/prognostic-value-of-resected-lymph-nodes-numbers-for-siewert-ii-gastroesophageal-junction-cancer
#15
Sanchuan Lai, Tingting Su, Xingkang He, Zhenghua Lin, Shujie Chen
We aim to evaluate whether resected lymph nodes (RLNs) numbers have prognostic value in patients with gastroesophageal junction cancers (GEJ, Siewert type II). Patients with gastroesophageal junction cancers were identified from the Surveillance Epidemiology and End Results (SEER) registry between 1988 to 2013. Multivariate Cox regression analyses and Kaplan-Meier method were performed to analyze risk factors for overall survival (OS) and cause-specific survival(CSS). A total of 8396 patients who underwent surgeries and had reginal lymph nodes examined were identified...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29397460/ramucirumab-for-the-treatment-of-patients-with-gastric-or-gastroesophageal-junction-cancer-in-community-oncology-practices
#16
A Scott Paulson, Lisa M Hess, Astra M Liepa, Zhanglin Lin Cui, Kathleen M Aguilar, Jamyia Clark, William Schelman
BACKGROUND: Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer. This study was designed to describe ramucirumab monotherapy or combination therapy use in a community oncology practice setting. METHODS: This was a retrospective observational cohort study to describe the treatment of adult patients with gastric or GEJ cancer who initiated ramucirumab treatment between 4/21/14 and 6/30/16 within the US Oncology Network...
February 3, 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29370182/correlation-of-pathological-complete-response-with-survival-after-neoadjuvant-chemotherapy-in-gastric-or-gastroesophageal-junction-cancer-treated-with-radical-surgery-a-meta-analysis
#17
Ziyu Li, Fei Shan, Yinkui Wang, Yan Zhang, Lianhai Zhang, Shuangxi Li, Yongning Jia, Kan Xue, Rulin Miao, Zhemin Li, Jiafu Ji
BACKGROUND: Neoadjuvant chemotherapy before radical gastrectomy is preferred for locally advanced gastric cancer. To avoid the problematic use of pTNM for patients after neoadjuvant chemotherapy, the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) gastric cancer TNM staging system (8th edition) added ypTNM for the first time. But patients achieving pathological complete response were not covered by the new ypTNM staging system. To investigate whether pathological complete response is associated with better outcome in gastric cancer, as was reported in rectal, breast and bladder cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29350579/evaluation-of-respiratory-motion-corrected-cone-beam-ct-at-end-expiration-in-abdominal-radiotherapy-sites-a-prospective-study
#18
Russell E Kincaid, Agung E Hertanto, Yu-Chi Hu, Abraham J Wu, Karyn A Goodman, Hai D Pham, Ellen D Yorke, Qinghui Zhang, Qing Chen, Gig S Mageras
BACKGROUND: Cone beam computed tomography (CBCT) for radiotherapy image guidance suffers from respiratory motion artifacts. This limits soft tissue visualization and localization accuracy, particularly in abdominal sites. We report on a prospective study of respiratory motion-corrected (RMC)-CBCT to evaluate its efficacy in localizing abdominal organs and improving soft tissue visibility at end expiration. MATERIAL AND METHODS: In an IRB approved study, 11 patients with gastroesophageal junction (GEJ) cancer and five with pancreatic cancer underwent a respiration-correlated CT (4DCT), a respiration-gated CBCT (G-CBCT) near end expiration and a one-minute free-breathing CBCT scan on a single treatment day...
January 19, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29340092/first-line-dose-dense-chemotherapy-with-docetaxel-cisplatin-folinic-acid-and-5-fluorouracil-dcf-plus-panitumumab-in-patients-with-locally-advanced-or-metastatic-cancer-of-the-stomach-or-gastroesophageal-junction-final-results-and-biomarker-analysis-from-an
#19
Gianluca Tomasello, Nicola Valeri, Michele Ghidini, Elizabeth C Smyth, Wanda Liguigli, Laura Toppo, Rodolfo Mattioli, Alessandra Curti, Jens C Hahne, Federica M Negri, Stefano Panni, Margherita Ratti, Silvia Lazzarelli, Fabiana Gerevini, Chiara Colombi, Andrea Panni, Massimo Rovatti, Leonardo Treccani, Mario Martinotti, Rodolfo Passalacqua
Background: Survival for patients with advanced gastroesophageal cancer (AGC) using standard treatment regimens is poor. EGFR overexpression is common in AGC and associated with poor prognosis. We hypothesized that increasing the dose intensity of chemotherapy and adding panitumumab could improve efficacy. Methods: HER2 negative, PS 0-1 patients, received up to 4 cycles of panitumumab 6 mg/kg d 1, docetaxel 60 mg/m2 d 1, cisplatin 50 mg/m2 d 1, l-folinic acid 100 mg/m2 d 1-2, followed by 5-FU 400 mg/m2 bolus d 1-2, and then 600 mg/m2 as a 22 h c...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29333068/nab-paclitaxel-as-second-line-treatment-in-advanced-gastric-cancer-a-multicenter-phase-ii-study-of-the-hellenic-oncology-research-group
#20
Panagiotis Katsaounis, Athanasios Kotsakis, Nikolaos Kentepozidis, Aris Polyzos, Marios Bakogeorgos, Filippos Koinis, Lambros Vamvakas, Nikolaos Vardakis, Kostas Kalbakis, Ioannis Boukovinas, Ioannis I Varthalitis, Efthimios Prinarakis, Vassilis Georgoulias, John Souglakos
Background: This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma. Methods: Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and fluorouracil)] and 6 with combination of fluoropyrimidines plus cisplatin with locally advanced inoperable and metastatic gastric and gastroesophageal junction adenocarcinoma were treated with weekly nab-paclitaxel (150 mg/m2 d1, d8, d15 in cycles of 28 days)...
January 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
keyword
keyword
50345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"